Literature DB >> 19779801

HCV genotype 1b chimeric replicon with NS5B of JFH-1 exhibited resistance to cyclosporine A.

Ken-ichi Abe1, Masanori Ikeda, Yasuo Ariumi, Hiromichi Dansako, Takaji Wakita, Nobuyuki Kato.   

Abstract

Cyclosporine A (CsA) is a well-characterized anti-HCV reagent. Recently it was reported that the genotype 2a JFH-1 strain was more resistant than genotype 1 HCV strains to CsA in a cell culture system. However, the JFH-1 responsible region for the resistance to CsA remains unclear. It was also demonstrated that in genotype 1b HCVs, NS5B interacts with cyclophilin (CyP). To clarify whether or not NS5B of JFH-1 is significant for CsA resistance, we developed a chimeric replicon with NS5B of JFH-1 in the genotype 1b backbone. The chimeric replicon was more resistant to CsA than the parental genotype 1b replicon. Furthermore, reduction of CyPA had a greater effect on HCV RNA replication and sensitivity to CsA than reduction of CyPB. Here, we demonstrated that NS5B of JFH-1 contributed to this strain's CsA-resistant phenotype. NS5B and CyPA are significant for determining HCV's sensitivity to CsA.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19779801     DOI: 10.1007/s00705-009-0502-x

Source DB:  PubMed          Journal:  Arch Virol        ISSN: 0304-8608            Impact factor:   2.574


  6 in total

Review 1.  Chaperones in hepatitis C virus infection.

Authors:  Ronik Khachatoorian; Samuel W French
Journal:  World J Hepatol       Date:  2016-01-08

2.  A major determinant of cyclophilin dependence and cyclosporine susceptibility of hepatitis C virus identified by a genetic approach.

Authors:  Feng Yang; Jason M Robotham; Henry Grise; Stephen Frausto; Vanesa Madan; Margarita Zayas; Ralf Bartenschlager; Margaret Robinson; Andrew E Greenstein; Anita Nag; Timothy M Logan; Ewa Bienkiewicz; Hengli Tang
Journal:  PLoS Pathog       Date:  2010-09-23       Impact factor: 6.823

3.  HCV resistance to cyclosporin A does not correlate with a resistance of the NS5A-cyclophilin A interaction to cyclophilin inhibitors.

Authors:  Udayan Chatterji; Precious Lim; Michael D Bobardt; Stefan Wieland; Daniel G Cordek; Gregoire Vuagniaux; Francis Chisari; Craig E Cameron; Paul Targett-Adams; Tanya Parkinson; Philippe A Gallay
Journal:  J Hepatol       Date:  2010-04-03       Impact factor: 25.083

4.  Cyclophilin inhibitors as a novel HCV therapy.

Authors:  Hengli Tang
Journal:  Viruses       Date:  2010-08-05       Impact factor: 5.818

5.  The ESCRT system is required for hepatitis C virus production.

Authors:  Yasuo Ariumi; Misao Kuroki; Masatoshi Maki; Masanori Ikeda; Hiromichi Dansako; Takaji Wakita; Nobuyuki Kato
Journal:  PLoS One       Date:  2011-01-11       Impact factor: 3.240

6.  Cyclophilin inhibitors as antiviral agents.

Authors:  Michael Peel; Andrew Scribner
Journal:  Bioorg Med Chem Lett       Date:  2013-06-10       Impact factor: 2.823

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.